2 The aims of this study were to examine the effects of 5-HT on the L-type Ca 2+ current (I CaL ) action potential duration, the effective refractory period (ERP) and arrhythmic activity in human atrial cells, and to assess the effects of prior treatment with β-adrenoceptor antagonists.
Introduction 5-hydroxytryptamine (5-HT) exerts a variety of effects in the heart, brain, adrenocortical cells, urinary bladder and alimentary canal via stimulation of the 5-HT 4 receptor sub-type (Hegde & Eglen, 1996) . The 5-HT 4 receptor is functionally present in the human atrium (Blondel et al., 1997) but not in the ventricle (Jahnel et al., 1992) , which has stimulated interest in its possible roles in the occurrence of atrial arrhythmia. It has been postulated that 5-HT is involved in the progression of atrial fibrillation (AF) in patients due to its release from aggregating platelets within the fibrillating atria (Kaumann, 1994) . In addition, there has been concern about the potential for atrial arrhythmia generation when using 5-HT 4 receptor agonists as gastrokinetic agents (Medhurst & Kaumann, 1993; Tonini et al., 1999) . In human atrial isolated muscle, arrhythmic contractions were induced by 5-HT, and abolished by a selective 5-HT 4 receptor antagonist (Kaumann & Sanders, 1994) . 5-HT has been shown to increase the magnitude of the L-type calcium current (I CaL ) in human atrial myocytes (Jahnel et al., 1993; Ouadid et al., 1992) , which may contribute to intracellular calcium overload and arrhythmic activity. However, in a study of a pig model of atrial flutter/AF (Rahme et al., 1999) , the 5-HT 4 receptor antagonist, RS-100302, was demonstrated to be anti-arrhythmic, associated with prolongation of the atrial effective refractory period (ERP). This suggested that 5-HT may shorten the atrial ERP, which may predispose to AF by reducing the minimum pathlength required for re-entry. The importance of these potential arrhythmogenic effects of 5-HT, namely calcium overload and/or shortened refractoriness, have not yet been clarified in human atria.
One factor that may influence the arrhythmogenic potential of 5-HT is the prior treatment of the patient with β-adrenoceptor antagonists. The ability of 5-HT to cause rate-dependent arrhythmic contractions in strips of human atrial tissue was facilitated by chronic β-blockade (Kaumann & Sanders, 1994; Sanders et al., 1995) . In addition, prior β-blocker treatment increased the positive inotropic response of human atrial muscle to 5-HT (Sanders et al., 1995; Wangemann et al., 2003) , but the influence of β-blockade on the effects of 5-HT on I CaL is unknown. We have recently reported that chronic β-blockade is associated with prolongation of the basal action potential duration (APD) and ERP in human atrial myocytes, and that this effect 5 is not related to a change in I CaL (Workman et al., 2003) . Such an increase in APD may result in increased contractile tension independent of I CaL (Bers, 2002) , and this may underlie the increased basal force of contraction in atrial strips from patients pre-treated with β 1 -adrenoceptor antagonists (Wangemann et al., 2003) . However, the ionic mechanism by which chronic β-blockade enhances the effects of 5-HT on human atria, and in particular whether I CaL is involved, has not been proven.
The aims of this work were: 1) to study how the increase in I CaL by 5-HT may affect the action potential morphology, the cellular refractoriness and the occurrence of arrhythmic activity, and 2) to investigate the influence of chronic β-blocker therapy on the actions of 5-HT on I CaL , APD, ERP and arrhythmic mechanism in human atrial single myocytes.
6
Methods

Tissue and cell isolation
The procedures for the removal of human tissue were approved by the institutional research ethics committee of Glasgow Royal Infirmary, and each patient's informed consent was obtained. The investigation conforms to the principles outlined in the Declaration of Helsinki (World Medical Association, 1997) . Specimens of the right atrial appendage were obtained from patients undergoing cardiac surgery. The excised tissue (weight: 0.45±0.06 g) was placed in Tyrode's solution and transported to the laboratory for processing within 5 min of removal. Atrial cells were isolated by enzymatic dissociation and mechanical disaggregation, using a modification of the chunk method, described in detail by Workman et al. (2001) .
Electrical recording techniques
Action potentials and ion currents were recorded using the whole cell patch clamp technique, with an Axopatch-1D amplifier (Axon Instruments). Cells were superfused at 37 o C at 1.5 ml min -1 (RC-24E fast exchange perfusion chamber, Warner) with a physiological salt solution containing (mM): NaCl (130.0), KCl (4.0), CaCl 2 (2.0), MgCl 2 (1.0), glucose (10.0), HEPES (10.0), pH 7.4. The perforated patch clamp technique, with nystatin (184 µM), was used to prevent cell dialysis, prolonging recording and minimising current "run-down".
Microelectrodes were constructed from thin walled, filamented borosilicate glass (Clark Electromedical) using a micropipette puller (Narishige PP-83), and heat polished to resistances of 3-9 MΩ. To record calcium currents, electrodes were filled with a caesium-based solution (to eliminate outward K + currents) containing (mM): CsCl (30.0), HEPES (5.0), MgCl 2 (1.0), Cs methanesulfonic acid (100.0), NaCl (5.0). To record action potentials, an internal potassiumbased solution was used, containing (mM): KCl (30.0), HEPES (5.0), MgCl 2 (1.0), K methanesulfonic acid (100.0), NaCl (5.0). Using these solutions, a liquid junction potential of +5.0±0.2 mV (n=6) was measured (bath relative to pipette) and was compensated for prior to seal formation (Neher, 1992) . Only single, elongated myocytes were selected for electrical recording. Following seal formation, a gradual reduction in the series resistance due to nystatin pore formation was observed, which stabilised (after ~10 min) at 11.1±0.5 MΩ (n=84 cells). Actions potentials were stimulated at 75 beats min -1 (bpm) using 5 ms current pulses of 1.2x threshold strength, after current clamping resting cells at -75 to -80 mV, and keeping the holding current (<150 pA) constant thereafter. The stimulus threshold current amplitude was initially determined in each cell by stimulating repetitively with trains of three current pulses (5 ms duration), the 1 st and 2 nd being of equal, suprathreshold amplitude, and the 3 rd pulse increasing progressively (from zero, in steps of 50 pA) until it produced a regenerative action potential. The stimulus strength was then kept constant throughout all recording protocols in each cell. The cell's ERP was measured using a standard S 1 -S 2 stimulation protocol, with an 8-pulse conditioning train delivered at 75 bpm, and with S 1 and S 2 pulses of equal magnitude. The S 1 -S 2 interval was shortened in 10 ms steps, and the ERP was defined as the longest S 1 -S 2 interval which failed to elicit an S 2 action potential of amplitude >80% of the preceding S 1 action potential. The APD was calculated as the interval between the action potential upstroke and repolarisation to the level of 50% (APD 50 ) and 90% (APD 90 ) of the upstroke amplitude. I CaL and/or action potentials and the ERP were recorded before, and 90 s after, drug additions and again 180 s after removal of drugs. 
Data analysis and statistics
Details of each patient's clinical characteristics and drug treatments were obtained from the case notes. The cardiac rhythm and heart rate were assessed from the pre-operative electrocardiogram. Only those patients in sinus rhythm at the time of surgery were included.
Cells were excluded from analysis if either the APD 50 or peak I CaL decreased irreversibly during the protocol. Concentration-response data for the effect of 5-HT on I CaL were fitted iteratively (Prism software, Graphpad) with variable slope sigmoidal concentration-response curves, using the Hill equation: ) was used to assess the level of significance of differences in the incidences of arrhythmic activity between groups. P<0.05 was regarded as statistically significant.
Results
Patients' characteristics
The majority of patients were male, underwent coronary artery bypass graft surgery, suffered from angina, and had normal left ventricular function (Table 1) . Fifty-nine percent of the patients were taking β-adrenoceptor blockers, and 59% calcium channel blockers. Of the patients taking β-blockers, 50% were also receiving calcium channel blockers. All patients undergoing β-blockade were treated for >1 month with cardiac selective β 1 -adrenoceptor antagonists, namely atenolol (69%), bisoprolol (19%) or metoprolol (12%). No patient was administered sotalol (which has additional class III anti-arrhythmic activity) except for 1 patient who was changed from sotalol to atenolol 1 week prior to surgery. Patients received their routine cardiac drugs on the day of surgery. Of the patients treated with calcium channel blockers, 44% were receiving diltiazem, a cardiac-acting drug, and the remaining 56% were taking dihydropyridines, with mainly vascular actions, namely amlodipine (38%), felodipine (12%) and nifedipine (6%). The heart rate was significantly reduced in β-blocked (62±4 bpm, n=16) compared to non-β-blocked patients (75±3 bpm, P<0.05; n=11), but was not altered by calcium channel blocker therapy (68±6 vs 66±3 bpm, for treated and non-treated patients, respectively).
Effects of 5-HT and GR-113808 on the calcium current in human atrial cells
5-HT produced a substantial increase in the amplitude of I CaL , as shown by the original recordings in Figure 1a , and by the I CaL current density-voltage relationships in Figure 1b 
The concentration-response relationship of the effect of 5-HT on I CaL
The effect of 5-HT on I CaL was concentration dependent. Figure 3a shows the concentration-response curve of the effect of 5-HT between 1 nM and 10 µM, fitted to the mean values obtained at each concentration. The log EC 50 calculated from this curve was -7.15±0.05, and the Hill coefficient (n H ) was 1.37±0.28 (n=17-33 cells, 9-17 patients). The maximum response of I CaL to 5-HT (E max ) was observed to occur at around 1 µM 5-HT, with a value of 267±7%.
In Figure 3b , the 5-HT concentration-response data has been sub-divided into those obtained from patients with and without prior treatment with β-blockers. The respective log EC 50 (-7.09±0.07 and -7.26±0.06) and n H (1.5±0.6 and 1.5±0.3) values were not significantly different between these patient groups. By contrast, 5-HT caused a significantly greater increase in E max in β-blocked (at 299±12%, n=9-18 cells, 4-11 patients) than in non-β-blocked patients (at 220±6%, n=8-15 cells, 5-7 patients; P<0.05) (Figure 3b ). There was no significant difference in basal I CaL between non-β-blocked (-5.4±0.7 pA pF -1 , n=30) and β-blocked patients (-4.2±0.3 pA pF -1 , n=50).
Pre-treatment with calcium channel blockers did not significantly alter the concentration-response curves to 5-HT on I CaL . Similarly, basal I CaL was not significantly different between cells from patients who had, and those from patients who had not received calcium channel blockers, at -4.8±0.6 (n=32) and -4.5±0.4 pA pF -1 (n=48), respectively. 12
Effect of 5-HT on action potentials and the refractory period
Effects of 5-HT on arrhythmic activity in human atrial cells
Chronic β-blockade was associated with an increased incidence of 5-HT-induced atrial cellular arrhythmic activity. 
Discussion
The present work has demonstrated, for the first time to our knowledge, that the effects of 5-HT to increase the L-type Ca 2+ current and to prolong the early plateau phase of action potential repolarisation in human atrial myocytes were each potentiated by prior treatment of patients with β-blockers, with evidence of arrhythmogenic activity. Since 5-HT had no effect on late repolarisation or refractoriness, it would not be expected to contribute to the shortening of re-entrant circuits which stabilises AF. It is more likely that 5-HT may contribute to arrhythmia genesis, by causing afterdepolarisations via mechanisms involving increased I CaL and cellular calcium overload (Levy, 1989) .
Atrial fibrillation is known to be associated with platelet activation (Kamath et al., 2001) , and it has been proposed that the consequent release of 5-HT may be involved in the progression of the arrhythmia (Kaumann, 1994) . The concentration of free 5-HT in human whole blood has been reported to range from nanomolar, rising to nearly micromolar, levels after activation of platelets (Joseph et al., 1991) . The present results confirm that within this concentration range 5-HT has important electrophysiological effects on human atrial myocytes.
The novel finding of a prolongation by 5-HT of the early plateau phase of atrial action potential repolarisation, associated with plateau elevation, with no effect on late repolarisation or the ERP, is likely due to the observed increase in I CaL . Whilst an involvement of the transient outward K + current, I TO , which also contributes to early repolarisation, cannot be excluded, no reports of effects of 5-HT on I TO were found. Furthermore, a predominant contribution from I CaL is supported by a report that blockade of I CaL by nifedipine, a calcium channel blocker, markedly depressed the action potential plateau in human atrial cells, with a relatively small effect on late repolarisation and none on the ERP (Workman et al., 2001) . The increase in I CaL may contribute to the intracellular calcium overload that occurs in AF, which is thought to contribute to subsequent electrophysiological changes (Nattel, 1999) . The reported reduction in 5-HT 4 receptor mRNA in chronically fibrillating human atria may represent an adaptive response in order to reduce calcium entry (Grammer et al., 2001 ).
There has been only one previous, non-quantitative, study of the effect of 5-HT on human atrial action potentials, and 5-HT had no effect on action potential morphology but increased tension in muscle strips, and increased I CaL in myocytes (Jahnel et al., 1993) . In the present study, the majority of cells exhibited characteristic atrial type 3 action potentials (Dawodu et al., 1996) , ie: with a pronounced phase 1, and a plateau below the level of 50% repolarisation, making APD 50 more susceptible to changes in plateau amplitude, and hence inward currents.
There are no previous reports of the effects of 5-HT on the ERP in the human atrium. In a pig model of AF, the 5-HT 4 receptor antagonist, RS-100302, prolonged the ERP and was antiarrhythmic (Rahme et al., 1999) . If that effect was a consequence of 5-HT 4 receptor blockade in-vivo it suggested that 5-HT should reduce the ERP, which, by reducing the minimum pathlength required for re-entry, would promote AF (Moe, 1962) . Whilst this could represent a species-specific effect, or an additional direct action of the drug, it is also recognised that myocytes isolated by the "chunk" method may lack the delayed rectifier potassium current (Yue et al., 1996) . Thus, even if 5-HT increased this current in-vivo, shortening of late repolarisation and/or the ERP may not be observed in isolated cells. However, the report of an absence of effect of 5-HT on the action potential in intact human atrial muscle (Jahnel et al., 1993 ) makes this less likely, since ERP in human atrial myocytes is closely related to APD 90 (Workman et al., 2001 ).
The concentration dependent increase in I CaL , mediated via the 5-HT 4 receptor sub-type in the present report, with an EC 50 of about 70 nM, is consistent with that reported for I CaL in human atrial myocytes (Ouadid et al., 1992) but is also of a similar potency to that reported for the positive inotropic effect of 5-HT in human atrial preparations (Jahnel et al., 1992) . The present, novel observation of potentiation by β-blockade of the 5-HT effect on I CaL supports the likelihood that the reported positive inotropic action of 5-HT, which was also increased by β-blockade, is directly related to the increase in I CaL . Our finding of an increased efficacy, and no change in the EC 50 , of the effect of 5-HT on I CaL with β-blockade is in agreement with the increased maximal inotropic effect of 5-HT in human atrial strips, without change in potency, reported by Sanders et al. (1995) . This differs from data on cell shortening in the same study (increased potency, no increase in maximal response), but is supported by a recent report of sensitisation by β-blockade of inotropic responses to 5-HT in human atrial strips (Wangemann et al., 2003) . The reason for the discrepancy within the study of Sanders et al. (1995) , and with our results is unknown, but it suggests that the potentiation of the effect of 5-HT on I CaL is correlated better with the maximal inotropic response than with myocyte shortening.
Chronic β-blockade has recently been shown to increase basal APD 90 and ERP in human atrial myocytes, consistent with the trends in the present data, and this "pharmacological remodelling" was independent of an effect on I CaL (Workman et al., 2003) . By contrast, the present effects of β-blockade, on responses to 5-HT, appear more likely to be related to changes in the phosphorylation state of the calcium channel. This may be due to intracellular cross-talk between G s -coupled receptor populations, since chronic β  -adrenoceptor blockade enhances inotropic effects mediated by β 2 -adrenoceptors, histamine H 2 and 5-HT 4 stimulation (Wangemann et al., 2003) . It has been shown that the levels of mRNA encoding human atrial 5-HT 4 receptors were unaffected by chronic β-blockade (Grammer et al., 2001 ) and the affinity of the β 2 -adrenoceptor was also unaffected (Hall et al., 1990) . Thus, the increased efficacy of 5-HT with β-blockade that we, and others, have found is likely due to an enhancement of the intracellular biochemical cascade which links the receptor to calcium channels, rather than to changes in 5-HT 4 receptor density or affinity. An alteration in the activity of G-proteins may be involved (Grimm et al., 1998; Wang et al., 1999) and whilst expression of atrial G s and G i was unaffected by chronic β-blockade (Jia et al., 1995) , the activity of G s was enhanced (Wang et al., 1999) . Furthermore, 5-HT-induced increases in adenylyl cyclase activity (Wangemann et al., 2003) and intracellular cAMP (Jahnel et al., 1993) , leading to channel phosphorylation and increased I CaL availability, are potentiated in atrial tissue from β-blocked patients.
In conclusion, these data indicate that, in the human atrium, the 5-HT-induced increase in calcium current is associated with a prolonged early plateau phase of repolarisation, but not late repolarisation or refractoriness, and that the enhancement of these effects by chronic β-adrenoceptor blockade is associated with arrhythmic potential. They provide further support for the hypothesis that 5-HT released by aggregating platelets during AF, or 5-HT 4 receptor agonists as therapeutic agents, may contribute to the origin and maintenance of atrial arrhythmia. interval failing to elicit an S 2 response of amplitude >80% of the preceding S 1 action potential.
The S 2 response used to measure this interval is labelled with an arrow. 
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